Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2012

View Archived Issues

Novel agents for migraine prepared at Merck & Co.

Jenrin Discovery designs novel compounds targeting the cannabinoid CB1 receptor

Pilot study evaluates iobenguane (131I) in newly diagnosed high-risk neuroblastoma

Novel anticancer TLR7 agonists disclosed

New agents for pulmonary hypertension presented by Ironwood Pharmaceuticals

Celgene patents novel inhibitors of mutant EGFR

U.S. researchers disclose novel metalloenzyme inhibitors

New antisense oligonucleotides designed at Japanese university

Instituto Biomar reports new agents from a marine microorganism

Novel prognostic marker for cervical cancer correlates with EGFR expression

Gilead characterizes bifunctional LABA/PDE4 inhibitor

Data from expanded moxetumomab trial support further testing

Phase I/II trial evaluates KW-2871 combination therapy in melanoma

Newron announces acquisition plan

JDRF and Novo Nordisk establish type 1 diabetes partnership

Upsher-Smith to acquire European biotechnology company

FDA grants orphan drug status to new Regenicin product

Azaya Therapeutics reports phase I liposomal docetaxel data

EMA's COMP issues opinion on Enhoxy

Biofrontera to pursue U.S. registration of Ameluz

Ophthotech reports results from Fovista/Lucentis study

Janssen clear to take FGFR kinase inhibitor into phase I trials

Kuros reports promising results on novel dural sealant

New SBIR grant supports malaria research at Sanaria and IBBR

SymBio product gets Japanese orphan drug status for CLL

Shionogi reports initial data from S-555739 trial in allergic rhinitis

FDA accepts NDA for Raptor Pharmaceuticals' nephropathic cystinosis drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...